C., M., T., B., T., T., S., T., H., V. V., S., Z., . . . G., D. S. (2017). Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study.
استشهاد بنمط شيكاغوC., Moreno, et al. Antiviral Activity of TMC435 Monotherapy in Patients Infected With HCV Genotypes 2-6: TMC435-C202, a Phase IIa, Open-label Study. 2017.
MLA استشهادC., Moreno, et al. Antiviral Activity of TMC435 Monotherapy in Patients Infected With HCV Genotypes 2-6: TMC435-C202, a Phase IIa, Open-label Study. 2017.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.